GlaxoSmithKline chiefs 'confess to bribing Chinese doctors'

Public Security Ministry announcement says GSK executives paid off healthcare staff to persuade them to prescribe drugs

Executives at the pharmaceuticals giant GlaxoSmithKline have been accused of bribing doctors in China, in a long-running campaign to persuade them to prescribe drugs to patients.

Officials from China's Public Security Ministry in an announcement alleged that the employees paid "large bribes," laundered through travel agencies, to doctors, hospitals and others to ""open new sales channels and increase drug revenues". Giving no specific time frame,  the announcement said the scheme had lasted a "long time".

Identifying the GSK employees as "high officials," the ministry said they are also suspected of tax offences involving collusion with travel agencies to issue false invoices, the ministry said. No details were given of the size of payments or who received them.

"After questioning, the suspects confessed to the crime," the statement said.

GSK said it would co-operate with the authorities but said today's announcement was the first official communication it has received about the investigation.

"Corruption has no place in our business," said a company statement. "If evidence of such activity is provided we would of course act swiftly on it."

A police ministry press office spokeswoman said she could not release the GSK employees' names or other details because they have not been charged with a crime.

Police in the central city of Changsha announced two weeks ago that GSK employees had been detained for questioning about unspecified "economic crimes." Today's statement said the investigation also took place in Shanghai and the central city of Zhengzhou.

GlaxoSmithKline said in June that it had investigated an accusation that its salespeople in China bribed doctors and found no evidence of wrongdoing. The company has said the police investigation might be based on information from the same anonymous source.

GlaxoSmithKline PLC is headquartered in Britain but has a presence in the United States, which could make it liable to penalties under US anti-bribery laws.

Last week, state media reported the government was investigating production costs for 60 foreign and domestic drug companies in a possible first step toward changing state-set maximum prices. The announcement gave no indication any companies were suspected of wrongdoing.

Comments